Pliant Therapeutics (PLRX) Net Income towards Common Stockholders (2019 - 2026)
Pliant Therapeutics (PLRX) reported Net Income towards Common Stockholders of -$20.0 million for Q1 2026, up 64.32% year-over-year from -$12.2 million in Q1 2025, and up 7.86% quarter-over-quarter from -$21.7 million in Q4 2025.
Pliant Therapeutics (PLRX) Net Income towards Common Stockholders (2019 - 2026) Analysis & Trends
Pliant Therapeutics (PLRX) has 8 years of Net Income towards Common Stockholders data on file, last reported at -$20.0 million in Q1 2026.
- Net Income towards Common Stockholders for Q1 2026 came in at -$20.0 million, up 64.32% year-over-year; the trailing twelve-month figure through Mar 2026 was -$111.4 million (up 49.26% YoY), and the FY2025 annual result was -$147.5 million, up 29.86% from the prior year.
- Net Income towards Common Stockholders climbed to -$20.0 million in Q1 2026 per PLRX's latest filing, from -$21.7 million in the prior quarter.
- Over five years, Net Income towards Common Stockholders peaked at -$20.0 million in Q1 2026 and troughed at -$57.8 million in Q3 2024.
- A 5-year average of -$39.0 million and a median of -$41.1 million in 2023 frame the typical range for Net Income towards Common Stockholders.
- The sharpest annual moves came in 2022 and 2026: Net Income towards Common Stockholders plunged 42.92% in 2022, then surged 64.32% in 2026.
- A 5-year view of Net Income towards Common Stockholders shows it stood at -$35.1 million in 2022, then fell by 17.25% to -$41.1 million in 2023, then decreased by 20.98% to -$49.7 million in 2024, then jumped by 56.27% to -$21.7 million in 2025, then gained by 7.86% to -$20.0 million in 2026.
- Business Quant data shows PLRX's Net Income towards Common Stockholders at -$20.0 million in Q1 2026, -$21.7 million in Q4 2025, and -$26.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 719,706.53 Bn | 719,706.50 Bn | - | - |
| 2 | Belite Bio | 55,800.00 Bn | 55,800.00 Bn | - | -26.94 Mn |
| 3 | Quantum Biopharma | 18,182.30 Bn | 18,182.29 Bn | - | -13.56 Mn |
| 4 | Legend Biotech | 3,154.00 Bn | 3,153.71 Bn | 242.10 Mn | 2.50 Mn |
| 5 | Akari Therapeutics | 1,844.30 Bn | 1,844.29 Bn | - | -14.46 Mn |
| 6 | Evaxion A | 1,567.96 Bn | 1,567.94 Bn | - | -3.63 Mn |
| 7 | Psyence Biomedical | 251.43 Bn | 251.42 Bn | - | -1.50 Mn |
| 8 | Vertex Pharmaceuticals | 112.56 Bn | 105.31 Bn | 2.59 Bn | 1.03 Bn |
| 9 | Abivax | 94.37 Bn | 94.37 Bn | - | -56.48 Mn |
| 10 | Pliant Therapeutics | 71.07 Mn | 71.07 Mn | - | -20.04 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -20.04 Mn |
| Dec 31, 2025 | -21.75 Mn |
| Sep 30, 2025 | -26.30 Mn |
| Jun 30, 2025 | -43.30 Mn |
| Mar 31, 2025 | -56.17 Mn |
| Dec 31, 2024 | -49.73 Mn |
| Sep 30, 2024 | -57.76 Mn |
| Jun 30, 2024 | -55.85 Mn |
| Mar 31, 2024 | -46.96 Mn |
| Dec 31, 2023 | -41.11 Mn |
| Sep 30, 2023 | -41.49 Mn |
| Jun 30, 2023 | -41.19 Mn |
| Mar 31, 2023 | -37.55 Mn |
| Dec 31, 2022 | -35.06 Mn |
| Sep 30, 2022 | -30.62 Mn |
| Jun 30, 2022 | -29.55 Mn |
| Mar 31, 2022 | -28.10 Mn |
| Dec 31, 2021 | -24.53 Mn |
| Sep 30, 2021 | -27.05 Mn |
| Jun 30, 2021 | -22.83 Mn |